Search

Displaying results 541 - 550 of 7536 in total
  1. Drug

    Diphenylpyraline

    go.drugbank.com/drugs/DB01146
    Approved

    Antihistamines prevent, but do not reverse, responses mediated by histamine alone. … Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells.

    Mixtures: Emercreme No4 Ont EfaSynonyms: 4-(benzhydryloxy)-N-methylpiperidine
  2. Drug

    Trametinib

    go.drugbank.com/drugs/DB08911
    ApprovedInvestigational

    Originally developed by Japan Tobacco, trametinib was initially investigated for treating inflammation, but further studies for this indication were not pursued.[A258298] … [A258298] It was later approved by Health Canada on July 18, 2013 [L45588] and by the European Commission on June 30, 2014.

  3. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    limited or no alternative oral treatment options. … [L57979,L57980] It retains activity against many extended-spectrum beta-lactamase producers but not against organisms producing serine or metallo-carbapenemases.

  4. Drug

    Atorvastatin

    go.drugbank.com/drugs/DB01076
    ApprovedInvestigational

    [A181397, A181403] Atorvastatin was first synthesized in 1985 by Dr. Bruce Roth and approved by the FDA in 1996. … [T568] It is a pentasubstituted pyrrole [A177415] formed by two contrasting moieties with an achiral heterocyclic core unit and a 3,5-dihydroxypentanoyl side chain identical to its parent compound.

    Products: Nb-atorvastatin
  5. Drug

    Technetium Tc-99m nofetumomab merpentan

    go.drugbank.com/drugs/DB09336
    ApprovedWithdrawn

    [FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. … It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082]

  6. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … (ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages.

  7. Drug

    Imdevimab

    go.drugbank.com/drugs/DB15940
    ApprovedInvestigational

    Casirivimab and imdevimab are investigational recombinant human IgG1 monoclonal antibodies that, at this time, are not officially approved by the FDA. … [L23524] In November 2021, the same indication was approved by the EMA.

  8. Drug

    Berdazimer

    go.drugbank.com/drugs/DB18712
    Approved

    It releases NO through exposure to proton donors like water, which will degrade the N-diazeniumdiolate entity. … Berdazimer is a polymeric substance consisting of a polysiloxane backbone (Si-O-Si bonds) with covalently bound N-diazeniumdiolate nitric oxide (NO) donors.

  9. Drug

    Oxymetholone

    go.drugbank.com/drugs/DB06412
    ApprovedIllicit

    In 2009, no producers of oxymetholone were identified worldwide (SRI 2009), but it was available from 14 suppliers, including 8 U.S. suppliers (ChemSources 2009). … Oxymetholone is a synthetic anabolic steroid marketed under the brand name Anapolon by Hoffmann La Roche Limitedand used in the treatment of osteoporosis, anaemia, and as an agent to stimulate muscle growth

  10. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … Acetarsol, with the molecular formula N-acetyl-4-hydroxy-m-arsanilic acid, is a pentavalent arsenical compound with antiprotozoal and antihelmintic properties.

    Mixtures: Neo Vagex